Skip to Main content Skip to Navigation
Journal articles

Evidence for a dominant negative disease mechanism in cap myopathy due to TPM3.

Abstract : We report a third patient with typical cap myopathy due to a heterozygous TPM3 mutation, confirming the importance of this causal association. The p.R168C TPM3 mutation we identified has been reported in two previous patients. The histological changes associated with this mutation vary widely from typical cap myopathy with near complete type 1 predominance (two patients), to typical congenital fibre-type disproportion without protein inclusions (one patient). We performed 2D-gel electrophoresis using muscle biopsies from two patients with the p.R168C mutation and show that mutant protein accounts for around 50% of alpha-tropomyosin(slow) in sarcomeres, consistent with a dominant negative mechanism of disease pathogenesis.
Document type :
Journal articles
Complete list of metadata

Cited literature [13 references]  Display  Hide  Download
Contributor : Nathalie Roux-Buisson Connect in order to contact the contributor
Submitted on : Wednesday, July 13, 2011 - 1:13:41 PM
Last modification on : Thursday, May 20, 2021 - 4:50:02 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Leigh B. Waddell, Michaela Kreissl, Andrew J. Kornberg, Paul Kennedy, Catriona Mclean, et al.. Evidence for a dominant negative disease mechanism in cap myopathy due to TPM3.. Neuromuscul Disord, 2010, 20 (7), pp.464-6. ⟨10.1016/j.nmd.2010.05.012⟩. ⟨inserm-00589053⟩



Record views